Advanced search
Publication Cover
International Journal of Hyperthermia Volume 33, 2017 - Issue 3
Submit an article Journal homepage
965
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

HSP90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line*

Arin N. GranerDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; View further author information
,
Justin E. HellwinkelDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; ;School of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; View further author information
,
Alex M. LencioniDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; ;University of Arkansas for Medical Sciences, Little Rock, AR, USA; View further author information
,
Helen J. MadsenDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; ;School of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; View further author information
,
Tessa A. HarlandDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; ;School of Medicine, University of Colorado School of Medicine, Aurora, CO, USA; View further author information
,
Paul MarchandoDepartment of Chemical and Biological Engineering, University of Colorado Boulder, Boulder, CO, USA; View further author information
,
Ger J. NguyenDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; View further author information
,
Mary WangDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; View further author information
,
Laura M. RussellDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; View further author information
,
Lynne T. BemisDepartment of Biomedical Sciences, University of Minnesota, Duluth, MN, USA; View further author information
,
Thomas J. AnchordoquySkaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Aurora, CO, USAView further author information
&
Michael W. GranerDepartment of Neurosurgery, University of Colorado Denver, Aurora, CO, USA; Correspondence[email protected]
View further author information
 show all
Pages 303-317 | Received 15 Aug 2016, Accepted 31 Oct 2016, Published online: 20 Dec 2016

References

  • Graner MW, Bigner DD. (2005). Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol 7:260–78.
  • Graner MW, Bigner DD. (2006). Therapeutic aspects of chaperones/heat-shock proteins in neuro-oncology. Expert Rev Anticancer Ther 6:679–95.
  • Ackerman D, Simon MC. (2014). Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol 24:472–8.
  • Cattaneo M, Dominici R, Cardano M, et al. (2012). Molecular chaperones as therapeutic targets to counteract proteostasis defects. J Cell Physiol 227:1226–34.
  • Shah SP, Lonial S, Boise LH. (2015). When cancer fights back: multiple myeloma, proteasome inhibition, and the heat-shock response. Mol Cancer Res 13:1163–73.
  • Sanghera SS, Skitzki JJ. (2013). Targeting the heat shock response in cancer: tipping the balance in transformed cells. Surg Oncol Clin N Am 22:665–84.
  • Walter P, Ron D. (2011). The unfolded protein response: from stress pathway to homeostatic regulation. Science 334:1081–6.
  • Graner MW. (2013). The unfolded protein response in glioblastomas: passing the stress test. CNS Oncol 2:1–4. Epub November, 2013.
  • Dicks N, Gutierrez K, Michalak M, et al. (2015). Endoplasmic reticulum stress, genome damage, and cancer. Front Oncol 5:11.
  • van Ommeren R, Staudt MD, Xu H, Hebb MO. (2016). Advances in HSP27 and HSP90-targeting strategies for glioblastoma. J Neurooncol 127:209–19.
  • Taldone T, Ochiana SO, Patel PD, Chiosis G. (2014). Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharmacol Sci 35:592–603.
  • Graner MW. (2015). The unfolded protein response in glioblastomas: targetable or trouble? Future Sci OA 1(2). doi: 10.4155/fso.15.45.
  • Tatokoro M, Koga F, Yoshida S, Kihara K. (2015). Heat shock protein 90 targeting therapy: state of the art and future perspective. EXCLI J 14:48–58.
  • Butler LM, Ferraldeschi R, Armstrong HK, et al. (2015). Maximizing the therapeutic potential of HSP90 inhibitors. Mol Cancer Res 13:1445–51.
  • Whitesell L, Santagata S, Lin NU. (2012). Inhibiting HSP90 to treat cancer: a strategy in evolution. Curr Mol Med 12:1108–24.
  • Wu BX, Hong F, Zhang Y, et al. (2016). GRP94/gp96 in cancer: biology, structure, immunology, and drug development. Adv Cancer Res 129:165–90.
  • Ansa-Addo EA, Thaxton J, Hong F, et al. (2016). Clients and oncogenic roles of molecular chaperone gp96/grp94. Curr Top Med Chem 16:2765–78.
  • Crowley VM, Khandelwal A, Mishra S, et al. (2016). Development of glucose regulated protein 94-selective inhibitors based on the BnIm and radamide scaffold. J Med Chem 59:3471–88.
  • Bourseau-Guilmain E, Menard JA, Lindqvist E, et al. (2016). Hypoxia regulates global membrane protein endocytosis through caveolin-1 in cancer cells. Nat Commun 7:11371.
  • Usmani SZ, Bona RD, Chiosis G, Li Z. (2010). The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol 3:40.
  • Epple LM, Bemis LT, Cavanaugh RP, et al. (2013). Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperther 29:390–8.
  • Redzic JS, Gomez JD, Hellwinkel JE, et al. (2016). Proteomic analyses of brain tumor cell lines amidst the unfolded protein response. Oncotarget. [Epub ahead of print]. doi: 10.18632/oncotarget.10032.
  • Epple LM, Dodd RD, Merz AL, et al. (2013). Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells. PLoS One 8:e73267.
  • Hellwinkel JE, Redzic JS, Harland TA, et al. (2016). Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol 18:497–506.
  • Raynes DA, Guerriero V. Jr. (1998). Inhibition of Hsp70 ATPase activity and protein renaturation by a novel Hsp70-binding protein. J Biol Chem 273:32883–8.
  • Karachaliou N, Rosell R, Molina MA, Viteri S. (2014). Predicting resistance by selection of signaling pathways. Transl Lung Cancer Res 3:107–15.
  • Meyuhas O. (2015). Ribosomal protein S6 phosphorylation: four decades of research. Int Rev Cell Mol Biol 320:41–73.
  • Katsogiannou M, Andrieu C, Rocchi P. (2014). Heat shock protein 27 phosphorylation state is associated with cancer progression. Front Genet 5:346.
  • Kostenko S, Moens U. (2009). Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell Mol Life Sci 66:3289–307.
  • Danial NN. (2008). BAD: undertaker by night, candyman by day. Oncogene 27:S53–S70.
  • Garcia A, Cayla X, Guergnon J, et al. (2003). Serine/threonine protein phosphatases PP1 and PP2A are key players in apoptosis. Biochimie 85:721–6.
  • Jiang P, Du W, Heese K, Wu M. (2006). The Bad guy cooperates with good cop p53: bad is transcriptionally up-regulated by p53 and forms a Bad/p53 complex at the mitochondria to induce apoptosis. Mol Cell Biol 26:9071–82.
  • Dai C, Gu W. (2010). p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med 16:528–36.
  • Decker P, Muller S. (2002). Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol 3:275–83.
  • Beurel E, Grieco SF, Jope RS. (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 148:114–31.
  • An WF, Germain AR, Bishop JA, et al. (2010). Discovery of potent and highly selective inhibitors of GSK3b. Probe reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010?2012 Apr 16 [updated 2014 May 13].
  • Hardie DG. (1999). Roles of the AMP-activated/SNF1 protein kinase family in the response to cellular stress. Biochem Soc Symp 64:13–27.
  • Zou J, Guo Y, Guettouche T, et al. (1998). Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94:471–80.
  • Chen F. (2012). JNK-induced apoptosis, compensatory growth, and cancer stem cells. Cancer Res 72:379–86.
  • Lotocki G, Alonso OF, Dietrich WD, Keane RW. (2004). Tumor necrosis factor receptor 1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain. J Neurosci 24:11010–16.
  • Nieto-Miguel T, Gajate C, Gonzalez-Camacho F, Mollinedo F. (2008). Proapoptotic role of Hsp90 by its interaction with c-Jun N-terminal kinase in lipid rafts in edelfosine-mediated antileukemic therapy. Oncogene 27:1779–87.
  • Wang C, Chen J. (2003). Phosphorylation and hsp90 binding mediate heat shock stabilization of p53. J Biol Chem 278:2066–71.
  • Liu Z, Ding Y, Ye N, et al. (2016). Direct activation of Bax protein for cancer therapy. Med Res Rev 36:313–41.
  • Thorburn A. (2004). Death receptor-induced cell killing. Cell Signal 16:139–44.
  • van Loo G, Saelens X, van Gurp M, et al. (2002). The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ 9:1031–42.
  • Zou H, Li Y, Liu X, Wang X. (1999). An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274:11549–56.
  • Smeenk L, van Heeringen SJ, Koeppel M, et al. (2011). Role of p53 serine 46 in p53 target gene regulation. PLoS One 6:e17574.
  • Meek DW. (2015). Regulation of the p53 response and its relationship to cancer. Biochem J 469:325–46.
  • Weyhenmeyer B, Murphy AC, Prehn JH, Murphy BM. (2012). Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer. Exp Oncol 34:192–9.
  • Bechtel W, Bauer G. (2009). Catalase protects tumor cells from apoptosis induction by intercellular ROS signaling. Anticancer Res 29:4541–57.
  • Devarajan A, Shih D, Reddy ST. (2014). Inflammation, infection, cancer and all that…the role of paraoxonases. Adv Exp Med Biol 824:33–41.
  • Yan B. (2011). Research progress on Livin protein: an inhibitor of apoptosis. Mol Cell Biochem 357:39–45.
  • Aggarwal BB, Bhardwaj U, Takada Y. (2004). Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors. Vitam Horm 67:453–83.
  • Semple JI, Smits VA, Fernaud JR, et al. (2007). Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell Death Differ 14:1433–42.
  • Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85.
  • Xu B, Wang W, Guo H, et al. (2014). Oxidative stress preferentially induces a subtype of micronuclei and mediates the genomic instability caused by p53 dysfunction. Mutat Res 770:1–8.
  • Albany C, Hahn NM. (2014). Heat shock and other apoptosis-related proteins as therapeutic targets in prostate cancer. Asian J Androl 16:359–63.
  • Wang C, Zhang Y, Guo K, et al. (2016). Heat shock proteins in hepatocellular carcinoma: molecular mechanism and therapeutic potential. Int J Cancer 138:1824–34.
  • Schipper HM. (2004). Heme oxygenase expression in human central nervous system disorders. Free Radic Biol Med 37:1995–2011.
  • Piret JP, Mottet D, Raes M, Michiels C. (2002). Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 64:889–92.
  • Zhu K, Chan W, Heymach J, et al. (2009). Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res 69:1836–43.
  • Ohkoshi S, Yano M, Matsuda Y. (2015). Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol 21:12150–6.
  • Dutto I, Tillhon M, Cazzalini O, et al. (2015). Biology of the cell cycle inhibitor p21 (CDKN1A): molecular mechanisms and relevance in chemical toxicology. Arch Toxicol 89:155–78.
  • Maddika S, Ande SR, Panigrahi S, et al. (2007). Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 10:13–29.
  • Taipale M, Jarosz DF, Lindquist S. (2010). HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11:515–28.
  • Marzec M, Eletto D, Argon Y. (2012). GRP94: an HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum. Biochim Biophys Acta 1823:774–87.
  • Eletto D, Dersh D, Argon Y. (2010). GRP94 in ER quality control and stress responses. Semin Cell Dev Biol 21:479–85.
  • Miyata Y, Nakamoto H, Neckers L. (2013). The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19:347–65.
  • Solarova Z, Mojzis J, Solar P. (2015). Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol 46:907–26.
  • Seo YH. (2015). Organelle-specific Hsp90 inhibitors. Arch Pharm Res 38:1582–90.
  • Trendowski M. (2015). PU-H71: an improvement on nature's solutions to oncogenic Hsp90 addiction. Pharmacol Res 99:202–16.
  • Liu Z, Zhong T, Zheng D, et al. (2016). Heat stress pretreatment decreases lipopolysaccharide-induced apoptosis via the p38 signaling pathway in human umbilical vein endothelial cells. Mol Med Rep 14:1007–13.
  • Rochani AK, Balasubramanian S, Ravindran Girija A, et al. (2016). Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation. Int J Pharm 511:648–58.
  • Yang R, Tang Q, Miao F, et al. (2015). Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice. Int J Nanomed 10:7345–58.
  • Chen Y, Youn P, Pysher TJ, et al. (2014) Tumour eradication using synchronous thermal ablation and Hsp90 chemotherapy with protein engineered triblock biopolymer-geldanamycin conjugates. Int J Hyperthermia 30:550–64.
  • Ohnishi K, Takahashi A, Yokota S, Ohnishi T. (2004). Effects of a heat shock protein inhibitor KNK437 on heat sensitivity and heat tolerance in human squamous cell carcinoma cell lines differing in p53 status. Int J Radiat Biol 80:607–14.
  • Kirpensteijn J, Kik M, Teske E, Rutteman GR. (2008). TP53 gene mutations in canine osteosarcoma. Vet Surg 37:454–60.
  • Queiroga FL, Raposo T, Carvalho MI, et al. (2011). Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 25:455–65.
  • Koshino A, Goto-Koshino Y, Setoguchi A, et al. (2016). Mutation of p53 gene and its correlation with the clinical outcome in dogs with lymphoma. J Vet Intern Med 30:223–9.
  • Ayrault O, Godeny MD, Dillon C, et al. (2009). Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma. Proc Natl Acad Sci USA 106:17037–42.
  • Lambrughi MD, Gioia L, Gervasio FL, et al. (2016). DNA-binding protects p53 from interactions with cofactors involved in transcription-independent functions. Nucleic Acids Res 44:9096–109.
  • Miyakoda M, Suzuki K, Kodama S, Watanabe M. (2002). Activation of ATM and phosphorylation of p53 by heat shock. Oncogene 21:1090–6.
  • Li D, Yallowitz A, Ozog L, Marchenko N. (2014). A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. Cell Death Dis 5:e1194.
  • Song S, Kole S, Precht P, et al. (2010). Activation of heat shock factor 1 plays a role in pyrrolidine dithiocarbamate-mediated expression of the co-chaperone BAG3. Int J Biochem Cell Biol 42:1856–63.
  • Isono T, Chano T, Kitamura A, Yuasa T. (2014). Glucose deprivation induces G2/M transition-arrest and cell death in N-GlcNAc2-modified protein-producing renal carcinoma cells. PLoS One 9:e96168.
  • Lopez I, Tournillon AS, Nylander K, Fahraeus R. (2015). p53-mediated control of gene expression via mRNA translation during endoplasmic reticulum stress. Cell Cycle 14:3373–8.
  • Bourougaa K, Naski N, Boularan C, et al. (2010). Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol Cell 38:78–88.
  • Obata T, Brown GE, Yaffe MB. (2000). MAP kinase pathways activated by stress: the p38 MAPK pathway. Crit Care Med 28:N67–77.
  • Dorion S, Landry J. (2002). Activation of the mitogen-activated protein kinase pathways by heat shock. Cell Stress Chaperones 7:200–6.
  • Darling NJ, Cook SJ. (2014). The role of MAPK signalling pathways in the response to endoplasmic reticulum stress. Biochim Biophys Acta 1843:2150–63.
  • Li C, Xu J, Li F, et al. (2011). Unfolded protein response signaling and MAP kinase pathways underlie pathogenesis of arsenic-induced cutaneous inflammation. Cancer Prev Res (Phila) 4:2101–9.
  • Lu J, Wang Q, Huang L, et al. (2012). Palmitate causes endoplasmic reticulum stress and apoptosis in human mesenchymal stem cells: prevention by AMPK activator. Endocrinology 153:5275–84.
  • Sekine Y, Takeda K, Ichijo H. (2006). The ASK1-MAP kinase signaling in ER stress and neurodegenerative diseases. Curr Mol Med 6:87–97.
  • Zhang R, Luo D, Miao R, et al. (2005). Hsp90-Akt phosphorylates ASK1 and inhibits ASK1-mediated apoptosis. Oncogene 24:3954–63.
  • Yong HY, Koh MS, Moon A. (2009). The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opin Investig Drugs 18:1893–905.
  • Neznanov N, Komarov AP, Neznanova L, et al. (2011). Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2:209–21.
  • Ri M. (2016). Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol 104:273–80.
  • Zismanov V, Drucker L, Gottfried M. (2014). Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration. Anticancer Drugs 25:998–1006.
  • Kato H, Nishitoh H. (2015). Stress responses from the endoplasmic reticulum in cancer. Front Oncol 5:93.
  • Patterson J, Palombella VJ, Fritz C, Normant E. (2008). IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells. Cancer Chemother Pharmacol 61:923–32.
  • Wang X, Wang S, Liu Y, et al. (2014). The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress. Biochem Biophys Res Commun 446:160–6.
  • Saha S, Bhanja P, Partanen A, et al. (2014). Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG. Oncoscience 1:434–45.
  • Gallerne C, Prola A, Lemaire C. (2013). Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta 1833:1356–66.
  • Green DR, Llambi F. (2015). Cell death signaling. Cold Spring Harbor Perspect Biol 7:a006080. doi: 10.1101/cshperspect.a006080.
  • Verma G, Datta M. (2012). The critical role of JNK in the ER-mitochondrial crosstalk during apoptotic cell death. J Cell Physiol 227:1791–5.
  • Siegelin MD. (2012). Utilization of the cellular stress response to sensitize cancer cells to TRAIL-mediated apoptosis. Expert Opin Ther Targets 16:801–17.
  • McCleese JK, Bear MD, Fossey SL, et al. (2009). The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int J Cancer 125:2792–801.
  • Sacco A, Aujay M, Morgan B, et al. (2011). Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. Clin Cancer Res 17:1753–64.
  • Rivas A, Vidal RL, Hetz C. (2015). Targeting the unfolded protein response for disease intervention. Expert Opin Ther Targets 19:1203–18.
  • Lafleur MA, Stevens JL, Lawrence JW. (2013). Xenobiotic perturbation of ER stress and the unfolded protein response. Toxicol Pathol 41:235–62.
  • MacEwen EG. (1990). Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 9:125–36.
  • Knapp DW, Dhawan D, Ostrander E. (2015). “Lassie,” “Toto,” and fellow pet dogs: poised to lead the way for advances in cancer prevention. Am Soc Clin Oncol Educ Book 2015:e667–72. doi: 10.14694/EdBook_AM.2015.35.e667.
  • London CA, Bear MD, McCleese J, et al. (2011). Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One 6:e27018.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.